Adverse effects of SGLT2 inhibitors on bone health

Nat Rev Nephrol. 2018 Aug;14(8):473-474. doi: 10.1038/s41581-018-0028-0.

Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors offer attractive metabolic and cardiorenal benefits for patients with type 2 diabetes, but are associated with a number of safety issues. A recent study documented that SGTL2 inhibition indirectly triggers the FGF23/1,25-dihydroxyvitamin D/parathyroid hormone axis, which may contribute to adverse effects on bone health.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Bone Demineralization, Pathologic / chemically induced*
  • Bone Density / drug effects
  • Canagliflozin / adverse effects
  • Fibroblast Growth Factors / blood*
  • Fractures, Bone / chemically induced*
  • Humans
  • Parathyroid Hormone / blood
  • Phosphorus / blood
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood

Substances

  • Parathyroid Hormone
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • Vitamin D
  • Phosphorus
  • Fibroblast Growth Factors
  • 1,25-dihydroxyvitamin D
  • fibroblast growth factor 23